Indeed, additional D‐2HG‐producing IDH1 mutations have been identified in non‐AML tumors, including IDH1 R100 in glioma, IDH1 G97 in colon cancer, and IDH1 Y139 in glioblastoma [14]. Here, IDH1 is linked to central nervous system cancer.